Crush or swallow? new study tests best way to take diabetes drug empagliflozin
NCT ID NCT06962826
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial in 14 healthy adults tested how the diabetes drug empagliflozin enters the body when taken as a whole tablet or dissolved in water and mixed with food. Researchers measured drug levels in the blood to compare absorption. The study aims to guide how the medication should be taken for best effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin
What this could lead to
If successful, this study could help doctors understand the best way to take empagliflozin for optimal absorption.
What could go wrong
This is a very small, early-phase study in healthy volunteers, so results may not apply to patients with diabetes or other conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany